Ontology highlight
ABSTRACT: Background
Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals.Case presentation
We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish function of its protein product, CASPR2. Homozygous family members display epilepsy, facial dysmorphisms, severe intellectual disability and impaired language. We compared these patients with previously reported individuals carrying homozygous mutations in CNTNAP2 and identified a highly recognisable phenotype.Conclusions
We propose that CASPR2 loss produces a syndrome involving early-onset refractory epilepsy, intellectual disability, language impairment and autistic features that can be recognized as CASPR2 deficiency disorder. Further screening for homozygous patients meeting these criteria, together with detailed phenotypic and molecular investigations will be crucial for understanding the contribution of CNTNAP2 to normal and disrupted development.
SUBMITTER: Rodenas-Cuadrado P
PROVIDER: S-EPMC4739328 | biostudies-literature | 2016 Feb
REPOSITORIES: biostudies-literature
Rodenas-Cuadrado Pedro P Pietrafusa Nicola N Francavilla Teresa T La Neve Angela A Striano Pasquale P Vernes Sonja C SC
BMC medical genetics 20160203
<h4>Background</h4>Heterozygous mutations in CNTNAP2 have been identified in patients with a range of complex phenotypes including intellectual disability, autism and schizophrenia. However heterozygous CNTNAP2 mutations are also found in the normal population. Conversely, homozygous mutations are rare in patient populations and have not been found in any unaffected individuals.<h4>Case presentation</h4>We describe a consanguineous family carrying a deletion in CNTNAP2 predicted to abolish funct ...[more]